OHIOCARE "DOUBLE REBATE" THREAT FOR PRESCRIPTION DRUG PROGRAM
Executive Summary
OHIOCARE "DOUBLE REBATE" THREAT FOR PRESCRIPTION DRUG PROGRAM is one of the "most pressing [issues] that we have fight now as a company and in the industry," Johnson & Johnson Manager of State Government Affairs Don Bohn told a National Pharmacy Forum on State Health Care Reform Legislation in Pentagon City, Va. June 24. A pending Ohio program to move Medicaid patients into managed care organizations for medical care and pharmaceuticals includes one clause which could obligate rebates from manufacturers to the state as well as substantial discounts to the managed Care programs.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth